Increased risk of infusion-related reactions switching between monoclonal antibodies for Alzheimer's disease: A case series - PubMed

3 hours ago

Monoclonal antibodies (mAbs) targeting amyloid plaques are increasingly used in early Alzheimer's disease (AD).
Infusion-related reactions (IRRs) are recognized class effects, but little is known about their occurrence when switching between anti-amyloid agents.
A retrospective case series of four patients who transitioned from aducanumab to lecanemab or donanemab was performed.
Four patients developed IRRs during or shortly after their first lecanemab infusion.
Pre-medication reduced recurrence of IRRs in some cases during subsequent infusions.
Prior exposure to mAbs may predispose some patients to more pronounced IRRs when switched to another agent in the class.
Larger observational studies are needed to establish the incidence, mechanisms, and best practices for prevention and management of IRRs.

Hasty Briefsbeta